Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.43M | 6.47M | 6.76M | 6.21M | 6.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.76M | 14.82M | 15.74M | 15.61M | 17.27M |
| Operating Income | -14.76M | -14.82M | -15.74M | -15.61M | -17.27M |
| Income Before Tax | -13.53M | -13.53M | -14.59M | -14.67M | -16.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.53 | -13.53 | -14.59 | -14.67 | -16.45 |
| Earnings from Discontinued Operations | -230.70K | -312.50K | -183.00K | -128.20K | 139.60K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.76M | -13.84M | -14.77M | -14.80M | -16.31M |
| EBIT | -14.76M | -14.82M | -15.74M | -15.61M | -17.27M |
| EBITDA | -2.63M | -6.05M | -11.01M | -15.54M | -17.19M |
| EPS Basic | -0.26 | -0.26 | -0.28 | -0.28 | -0.31 |
| Normalized Basic EPS | -0.16 | -0.16 | -0.17 | -0.18 | -0.20 |
| EPS Diluted | -0.26 | -0.26 | -0.28 | -0.28 | -0.31 |
| Normalized Diluted EPS | -0.16 | -0.16 | -0.17 | -0.18 | -0.20 |
| Average Basic Shares Outstanding | 210.50M | 210.17M | 209.66M | 209.14M | 208.60M |
| Average Diluted Shares Outstanding | 210.50M | 210.17M | 209.66M | 209.14M | 208.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
